Posts Tagged ‘Schutz’

Top 2011 IP Stories on Patents4Life

Saturday, December 31st, 2011

I spent a day or two looking back over the breaking IP news that resulted in posts on Patents4Life. I wrote most of them, but want to take a pause to thank regular contributors Paul Cole, Ron Schutz and Stefan Danner for their help. Patents4Life was originally intended to be a “blawg” focused on IP developments affecting the Life Sciences and, as 2011 comes to a close, I have put together a “top ten” list of stories to which attention had to be paid – by all of us in most cases – litigators, prosecutors and tech transfer professionals in the U.S. and abroad. The single most-apparent trend in IP last year was the increasing globalization of IP law – consider inter-office work-sharing and the prosecution highway. But I don’t want this column to go on into 2012, so here, in reverse order, are the “legal events” that dominated the netwaves in 2011. (I apologize for what I hope will be minor errors of fact and spelling – I am writing this from notes I made while back-tracking through the year.)

10. The Stem Cell Suits. In Sherley v. Sebelius, the district court finally dismissed the suit which had resulted in a ban on Federal funding for stem cell research, after the Court of appeals reversed its initial decision. (See Post, July 28th). However, in October, the Court of Justice of the EU ruled that claims to embryonic stem cells or even to cells that could become sources for embryonic stem cells were not patentable. (See post, Oct. 18th). Some types of gene therapy were indicated to be allowable. The future of embryonic stem cells is cloudy with a chance of further retreats like Geron’s.

9. On October 18th, Saint-Gobain petitioned for cert., urging the Supreme Court to answer a burden of proof question that comes down to: “Does holding a patent on an improvement on a patented invention that does not literally infringe insulate the accused infringer from infringement under the doctrine of equivalents?” This question has been simmering under the surface of infringement law for decades, the Fed. Cir. is clearly divided and the Supreme Court might bite. See Post of March 8, 2011 as well as October 14th post.

(more…)

Duties And Responsibilities Of A Corporate Fed. R. Civ. P. 30(B)(6) Witness

Friday, September 16th, 2011

The following is from the Robins, Kaplan, Miller & Ciresi newsletter BuLITS and written by Ron Schutz

Case: In re Neurontin Antitrust Litigation, 2011 U.S. Dist. LEXIS 62032, MDL No. 1479, Master File No. 02-1390 (D.N.J. 6/9/2011).

Facts:

Direct purchasers of the drug Neurontin brought an antitrust lawsuit claiming that the drug’s two manufacturers took part in a scheme to delay market entry of a generic version of the drug. Part of the alleged scheme included defendants’ illegal promotion of Neurontin for off-label uses. Both defendants denied the off-label promotion in their Answers to the plaintiffs’ Complaint, but defendant Pfizer had previously pled guilty to the illegal marketing in a separate criminal case.

(more…)

Happy Belated Birthday to Patents4Life! We are One.

Sunday, March 21st, 2010

Last Wednesday, Patents4Life forgot to celebrate its first anniversary. I have done a lot of writing, and recruiting of some writers (particular thanks to Paul Cole of Lucas & Co., UK, and Ronald J. Schutz of Robins Kaplan in Minneapolis for their posts on European law and practice and US litigation, respectively). I would also like to thank Mary Hirsch, the Marketing Director at SLW, for managing this site and getting it half-way organized. Of course I have a few thoughts, and will try to keep them short of a law review article.

Clearly, this is not the type of blog or tweeting thing whereby I share random thoughts on the state of IP today, in 165 characters or less. But neither is it exhaustive reporting and/or analysis of each and every decision, proposed rule, and bill relating to patent law and policy. (Even more clearly, I nearly flunked statistics in college, so no graphs for you!)

Patents4Life most closely resembles the now-defunct print newsletter, Patent Strategy and Management. The idea was to deliver short, timely, un-footnoted articles of interest to a wide range of technology acquisition and management professionals. It was a worthy concept, and I wrote for PSM for a number of years. But a good concept can be a bad idea, and print simply is not as timely as almost real-time reporters like PatentlyO, “Hal’s list”, Patent Baristas and now, Patents4Life.

I know sometimes “I do go on” (as my Alabama aunt might say) but I have been following some of these topics for years, e.g., ever since Chakrabarty was decided, Bayh-Dole was enacted and people started to try to patent the products of “genetic engineering” (not a term much in use today!). Yes, I can go on – and I hope to keep doing it for some years to come.

You Say Tomato . . . I Say Tah-mah-to . . . Hewlett-Packard Company v. Acceleron LLC

Monday, December 28th, 2009

Authored by Ronald J Schutz of Robins Kaplan Miller & Ciresi LLP

The Federal Circuit says: “declaratory judgment jurisdiction,” even if the patent holder’s notice letter waltzes around phrases like “infringement” or “assertion.” In Hewlett-Packard Company v. Acceleron LLC, the patent holder sent a letter that avoided using those phrases while still implying the possibility of litigation. The Federal Circuit said a patent holder cannot escape creating declaratory judgment jurisdiction simply by dodging certain words or phrases. Here, patent holder’s actions were “definite and concrete” enough to create a “substantial controversy.” Accordingly, the Federal Circuit reversed the district court’s determination that it lacked subject matter jurisdiction and remanded the claims for declarations of non-infringement and invalidity for further consideration — making it too late, presumably, for the patent holder to say “Let’s call the whole thing off.”

In Hewlett-Packard, a patent holding company owned the patent at issue. Within three months of acquiring the patent, the patent holder sent Hewlett-Packard a letter identifying certain HP products potentially impacted by its patent rights. The patent holder imposed a two-week deadline for execution of a letter agreeing, among other things, that Hewlett-Packard would not initiate litigation during negotiations. In response, Hewlett-Packard requested that the parties enter into a mutual no-litigation “standstill” agreement for 120 days. The patent holder refused and Hewlett-Packard filed its declaratory judgment action. Weighing the totality of the circumstances, the district court found that “the litigation was too speculative a prospect of support declaratory judgment jurisdiction.”

The Federal Circuit disagreed and specifically relied on MedImmune to reach its decision. While recognizing that the decision lowers the bar for what constitutes a justiciable controversy, the Federal Circuit said MedImmune nonetheless requires that a patent law declaratory judgment plaintiff demonstrate a dispute that is both “definite and concrete” and “real and substantial.” Not every fact pattern will rise to the necessary level of “a substantial controversy” and an objective review of the relevant facts is required. Necessary factors to be reviewed include consideration of whether the patent holder is a holding company or a competitor of the putative infringer, the patent holder’s history of enforcing the patent, the specific language used in any communications including their tone and implication and the status of relevant product lines and product plans. The Federal Circuit focused on the fact that the patent holder here was a patent holding company who, in response to the putative infringer’s answering letter, failed to agree to a confidentiality agreement or a mutual standstill of litigation that would have allowed the parties to engage in negotiations without litigation.

Either (or eye-ther), after Hewlett-Packard, regardless of what patent holders say, they most likely won’t be able to dance their way out of declaratory judgment jurisdiction if the reviewing court discerns an implied threat of litigation. Neither (nye-ther) should patent holders set overly burdensome conditions or precursors to further negotiations lest those demands become the evidence of a real dispute or controversy. Patent holders will also have to evaluate the use of “file, but not serve” rules in order to protect their chosen forum, but still engage in negotiation prior to full scale litigation.

Clearly, patent law declaratory judgment jurisprudence continues to evolve after MedImmune (leaving litigants on both side ample opportunities to argue that their unique facts should control). Still, no matter how you say it, after Hewlett-Packard, effectively initiating patent licensing negotiations while avoiding creating declaratory judgment jurisdiction remains patent law’s current hot potahto.